GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » Debt-to-EBITDA

Anteris Technologies (Anteris Technologies) Debt-to-EBITDA : -0.03 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Anteris Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.66 Mil. Anteris Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.02 Mil. Anteris Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-49.72 Mil. Anteris Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Anteris Technologies's Debt-to-EBITDA or its related term are showing as below:

AMEUF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.61   Med: -0.28   Max: -0.03
Current: -0.04

During the past 13 years, the highest Debt-to-EBITDA Ratio of Anteris Technologies was -0.03. The lowest was -0.61. And the median was -0.28.

AMEUF's Debt-to-EBITDA is ranked worse than
100% of 435 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs AMEUF: -0.04

Anteris Technologies Debt-to-EBITDA Historical Data

The historical data trend for Anteris Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anteris Technologies Debt-to-EBITDA Chart

Anteris Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.28 -0.28 -0.03 -0.04

Anteris Technologies Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.10 -0.03 -0.05 -0.03

Competitive Comparison of Anteris Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, Anteris Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anteris Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's Debt-to-EBITDA falls into.



Anteris Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Anteris Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.655 + 1.023) / -44.262
=-0.04

Anteris Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.655 + 1.023) / -49.722
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Anteris Technologies  (OTCPK:AMEUF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Anteris Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Anteris Technologies (Anteris Technologies) Business Description

Traded in Other Exchanges
Address
Level 3, 9 Sherwood Road, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.